Leerink Partnrs Brokers Increase Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Research analysts at Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a note issued to investors on Thursday, May 29th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2026 earnings at $2.78 EPS.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Robert W. Baird increased their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Truist Financial lowered their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Trading Down 0.2%

Shares of NYSE EW traded down $0.19 during mid-day trading on Monday, reaching $78.03. 3,374,673 shares of the company's stock were exchanged, compared to its average volume of 5,189,528. The firm has a market capitalization of $45.77 billion, a price-to-earnings ratio of 11.20, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $95.25. The company's 50-day moving average is $73.35 and its 200-day moving average is $72.50.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.66 EPS.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president now directly owns 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,012 shares of company stock valued at $4,224,717 in the last quarter. Corporate insiders own 1.29% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EW. Strs Ohio purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $9,486,000. Acadian Asset Management LLC raised its holdings in shares of Edwards Lifesciences by 191.9% in the first quarter. Acadian Asset Management LLC now owns 134,019 shares of the medical research company's stock valued at $9,708,000 after buying an additional 88,099 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Edwards Lifesciences by 7.2% during the first quarter. Geneos Wealth Management Inc. now owns 7,463 shares of the medical research company's stock worth $541,000 after buying an additional 503 shares during the period. Focus Partners Wealth grew its holdings in shares of Edwards Lifesciences by 6.1% during the first quarter. Focus Partners Wealth now owns 67,271 shares of the medical research company's stock worth $4,876,000 after buying an additional 3,891 shares during the last quarter. Finally, Integrity Alliance LLC. acquired a new position in Edwards Lifesciences in the 1st quarter valued at about $230,000. Institutional investors and hedge funds own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.